Masanori Yokono

Tsukuba, 3058585, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Effect of ASP5633, a novel peripherally restricted MT1/MT2 receptor agonist, on urethral function in female rats.

Effect of ASP5633, a novel peripherally restricted MT1/MT2 receptor agonist, on urethral function in female rats.

Journal: European journal of pharmacology

Published: September 25, 2025

Melatonin induces urethral contraction and increases intraurethral pressure via MT1 receptor activation in female rats.

Melatonin induces urethral contraction and increases intraurethral pressure via MT1 receptor activation in female rats.

Journal: European journal of pharmacology

Published: December 01, 2024

In Vitro Pharmacological Profile of Ipragliflozin, a Sodium Glucose Co-transporter 2 Inhibitor.

In Vitro Pharmacological Profile of Ipragliflozin, a Sodium Glucose Co-transporter 2 Inhibitor.

Journal: Biological & pharmaceutical bulletin

Published: March 05, 2019

Effect of ASP2205 fumarate, a novel 5-HT2C receptor agonist, on urethral closure function in rats.

Effect of ASP2205 fumarate, a novel 5-HT2C receptor agonist, on urethral closure function in rats.

Journal: Journal of pharmacological sciences

Published: January 15, 2019

Urethral function and histopathology in aged female rats as a stress urinary incontinence model.

Urethral function and histopathology in aged female rats as a stress urinary incontinence model.

Journal: Lower urinary tract symptoms

Published: July 24, 2017

Antidiabetic and antiobesity effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed sugar solution.

Antidiabetic and antiobesity effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed sugar solution.

Journal: European journal of pharmacology

Published: March 21, 2017

Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice.

Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice.

Journal: European journal of pharmacology

Published: January 26, 2017

Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: Part 2. Antidiabetic effects in type 2 diabetic mice.

Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: Part 2. Antidiabetic effects in type 2 diabetic mice.

Journal: Journal of pharmacological sciences

Published: March 07, 2016

Functional imaging of pharmacological action of SGLT2 inhibitor ipragliflozin via PET imaging using 11C-MDG.

Functional imaging of pharmacological action of SGLT2 inhibitor ipragliflozin via PET imaging using 11C-MDG.

Journal: Pharmacology research & perspectives

Published: December 09, 2015

Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.

Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.

Journal: Journal of pharmacological sciences

Published: November 23, 2015

Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice.

Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice.

Journal: Archives of pharmacal research

Published: February 09, 2015

SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats.

SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats.

Journal: European journal of pharmacology

Published: September 26, 2013

Showing 1-12 of 16

Last Updated: 09/26/2026